Nordic microbes A/SAktiv
Økonomiske nøgletal
Nøgletal
2025Balancens sammensætning
Selskabsskat
indkomstår 2024Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk
Regnskabstal2022–2025
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Balance — aktiver | ||||
| Likvide beholdninger | 2.796.877 | 34.845.836 | 12.350.008 | 21.800.566 |
| Omsætningsaktiver i alt | 5.304.094 | 38.403.615 | 17.884.486 | 26.567.384 |
| Anlægsaktiver i alt | 7.784.054 | 13.768.817 | 28.184.586 | 40.999.117 |
| Aktiver i alt | 13.088.148 | 52.172.432 | 46.069.072 | 67.566.501 |
| Balance — passiver | ||||
| Kortfristede gældsforpligtelser | 1.050.713 | 1.490.231 | 1.630.766 | 1.103.202 |
| Langfristede gældsforpligtelser | 4.160.000 | 0 | — | — |
| Gældsforpligtelser i alt | 5.210.713 | 1.490.231 | 1.630.766 | 1.103.202 |
| Selskabskapital | 55.265 | 402.520 | 402.520 | 481.849 |
| Overført resultat | 4.798.033 | 42.871.601 | 26.537.020 | 38.024.001 |
| Årets resultat | -2.161.140 | -4.526.454 | -6.523.266 | -11.315.953 |
| Egenkapital i alt | 7.877.435 | 50.682.201 | 44.158.935 | 66.298.858 |
| Resultatopgørelse | ||||
| Bruttofortjeneste | 3.423.504 | 4.541.580 | 6.147.617 | 4.894.958 |
| Resultat af primær drift | -2.880.170 | -5.878.346 | -9.801.907 | -14.947.607 |
| EBITDA | -2.646.334 | -5.076.912 | -7.808.731 | -11.266.234 |
| Resultat før skat | -3.090.233 | -5.927.143 | -8.611.236 | -14.849.621 |
| Årets resultat | -2.161.140 | -4.526.454 | -6.523.266 | -11.315.953 |
| Personaleomkostninger | 6.069.838 | 9.615.354 | 13.867.450 | 16.161.192 |
| Af- og nedskrivninger | 233.836 | 801.434 | 1.993.176 | 3.681.373 |
| Andre nøgletal | ||||
| Ansatte | 7 | 15 | 20 | 22 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2025Business reviewNordic microbes A/S, formerly Bioomix A/S, is a Danish ag-biotech company that develops, produces, and commercialises microbial products for agriculture. In 2025, Nordic microbes made significant progress towards its mission of making agriculture more productive, profitable, and sustainable through the use of microbial products. The company’s R&D activities focused primarily on the continued development and formulation of SeedSpeed and FungiFoe. This work resulted in the development of a storable powder formulation, for which production was successfully outsourced to an external manufacturing partner. During the year, the company also initiated the regulatory development of its biofungicide and conducted several successful third-party field trials with its products. Commercially, Nordic Microbes increased sales, achieved its first sales in the UK, expanded product use into maize and rapeseed, and initiated discussions and field trials with potential distributors across Europe. The commercial activities were supported by targeted marketing efforts, including customer case stories, video content, and participation in a range of agricultural events and trade shows. To support the company’s continued development, Nordic Microbes successfully raised additional equity and grant financing during the year. Entering 2026, Nordic Microbes is well-positioned for continued development and growth, supported by a strengthened product pipeline, a robust intellectual prope
Financial review The company's income statement for the year ended 31 December 2025 shows a loss of DKK 11.315.953, and the balance sheet at 31 December 2025 shows equity of DKK 66.298.858.
Uddrag af ledelsesberetningen i den seneste årsrapport.